Figure 1.
Cumulative incidence curves of cGVHD by day-100 biomarker thresholds and age group. Curves comparing 4 groups: high vs low CXCL9 (above [red] and below [blue] the threshold of 12 ng/mL, respectively) in either patients aged ≤10 years (solid line) or >10 years (dashed line), at post-HCT landmark day 100; ≤10, high CXCL9 (cGVHD, n = 2; no cGVHD, n = 2) vs low CXCL9 (cGVHD, n = 24; no cGVHD, n = 95), P = .095; >10, high CXCL9 (cGVHD, n = 7; no cGVHD, n = 5) vs low CXCL9 (cGVHD, n = 55; no cGVHD, n = 101), P = .035. Curves comparing 4 groups: high vs low IL1RL1 (above [red] and below [blue] the threshold of 18 ng/mL, respectively) in either patients aged ≤10 years (solid line) or >10 years (dashed line), at post-HCT landmark day 100; ≤10, high IL1RL1 (cGVHD, n = 15; no cGVHD, n = 36) vs low IL1RL1 (cGVHD, n = 11; no cGVHD, n = 61), P = .029; >10, high IL1RL1 (cGVHD, n = 43; no cGVHD, n = 53) vs low IL1RL1 (cGVHD, n = 19; no cGVHD, n = 53), P = .006. Curves comparing 4 groups: high vs low REG3α (above [red] and below [blue] the threshold of 50 ng/mL, respectively) in either patients aged ≥10 years (solid line) or >10 years (dashed line), at post-HCT landmark day +100; ≤10, high REG3α (cGVHD, n = 14; no cGVHD, n = 36) vs low REG3α (cGVHD, n = 12; no cGVHD, n = 61), P = .11; >10, high REG3α (cGVHD, n = 35; no cGVHD, n = 43) vs low REG3α (cGVHD, n = 27; no cGVHD, n = 63), P = .036. Curves comparing 4 groups: high vs low MMP3 (above [red] and below [blue] the threshold of 9 ng/mL, respectively) in either patients aged ≤10 years (solid line) or >10 years (dashed line), at post-HCT landmark day +100; ≤10, high MMP3 (cGVHD, n = 9; no cGVHD, n = 26) vs low MMP3 (cGVHD, n = 17; no cGVHD, n = 71), P = .50; >10, high MMP3 (cGVHD, n = 46; no cGVHD, n = 52) vs low MMP3 (cGVHD, n = 16; no cGVHD, n = 54), P = .002. Curves comparing 4 groups: high vs low DKK3 (above [red] and below [blue] the threshold of 48 ng/mL, respectively) in either patients aged ≤10 years (solid line) or >10 years (dashed line), at post-HCT landmark day +100; ≤10, high DKK3 (cGVHD, n = 11; no cGVHD, n = 23) vs low DKK3 (cGVHD, n = 12; no cGVHD, n = 58), P = .036; >10, high DKK3 (cGVHD, n = 25; no cGVHD, n = 27) vs low DKK3 (cGVHD, n = 25; no cGVHD, n = 62), P = .009. Curves comparing 4 groups: high vs low sCD163 (above [red] and below [blue] the threshold of 620 ng/mL, respectively) in either patients aged ≤10 years (solid line) or >10 years (dashed line), at post-HCT landmark day +100; ≤10, high sCD163 (cGVHD, n = 5; no cGVHD, n = 26) vs low sCD163 (cGVHD, n = 18; no cGVHD, n = 55), P = .46; >10, high sCD163 (cGVHD, n = 21; no cGVHD, n = 27) vs low sCD163 (cGVHD, n = 29; no cGVHD, n = 62), P = .055.

Cumulative incidence curves of cGVHD by day-100 biomarker thresholds and age group. Curves comparing 4 groups: high vs low CXCL9 (above [red] and below [blue] the threshold of 12 ng/mL, respectively) in either patients aged ≤10 years (solid line) or >10 years (dashed line), at post-HCT landmark day 100; ≤10, high CXCL9 (cGVHD, n = 2; no cGVHD, n = 2) vs low CXCL9 (cGVHD, n = 24; no cGVHD, n = 95), P = .095; >10, high CXCL9 (cGVHD, n = 7; no cGVHD, n = 5) vs low CXCL9 (cGVHD, n = 55; no cGVHD, n = 101), P = .035. Curves comparing 4 groups: high vs low IL1RL1 (above [red] and below [blue] the threshold of 18 ng/mL, respectively) in either patients aged ≤10 years (solid line) or >10 years (dashed line), at post-HCT landmark day 100; ≤10, high IL1RL1 (cGVHD, n = 15; no cGVHD, n = 36) vs low IL1RL1 (cGVHD, n = 11; no cGVHD, n = 61), P = .029; >10, high IL1RL1 (cGVHD, n = 43; no cGVHD, n = 53) vs low IL1RL1 (cGVHD, n = 19; no cGVHD, n = 53), P = .006. Curves comparing 4 groups: high vs low REG3α (above [red] and below [blue] the threshold of 50 ng/mL, respectively) in either patients aged ≥10 years (solid line) or >10 years (dashed line), at post-HCT landmark day +100; ≤10, high REG3α (cGVHD, n = 14; no cGVHD, n = 36) vs low REG3α (cGVHD, n = 12; no cGVHD, n = 61), P = .11; >10, high REG3α (cGVHD, n = 35; no cGVHD, n = 43) vs low REG3α (cGVHD, n = 27; no cGVHD, n = 63), P = .036. Curves comparing 4 groups: high vs low MMP3 (above [red] and below [blue] the threshold of 9 ng/mL, respectively) in either patients aged ≤10 years (solid line) or >10 years (dashed line), at post-HCT landmark day +100; ≤10, high MMP3 (cGVHD, n = 9; no cGVHD, n = 26) vs low MMP3 (cGVHD, n = 17; no cGVHD, n = 71), P = .50; >10, high MMP3 (cGVHD, n = 46; no cGVHD, n = 52) vs low MMP3 (cGVHD, n = 16; no cGVHD, n = 54), P = .002. Curves comparing 4 groups: high vs low DKK3 (above [red] and below [blue] the threshold of 48 ng/mL, respectively) in either patients aged ≤10 years (solid line) or >10 years (dashed line), at post-HCT landmark day +100; ≤10, high DKK3 (cGVHD, n = 11; no cGVHD, n = 23) vs low DKK3 (cGVHD, n = 12; no cGVHD, n = 58), P = .036; >10, high DKK3 (cGVHD, n = 25; no cGVHD, n = 27) vs low DKK3 (cGVHD, n = 25; no cGVHD, n = 62), P = .009. Curves comparing 4 groups: high vs low sCD163 (above [red] and below [blue] the threshold of 620 ng/mL, respectively) in either patients aged ≤10 years (solid line) or >10 years (dashed line), at post-HCT landmark day +100; ≤10, high sCD163 (cGVHD, n = 5; no cGVHD, n = 26) vs low sCD163 (cGVHD, n = 18; no cGVHD, n = 55), P = .46; >10, high sCD163 (cGVHD, n = 21; no cGVHD, n = 27) vs low sCD163 (cGVHD, n = 29; no cGVHD, n = 62), P = .055.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal